STAT Plus: Gilead loses another challenge to a pair of U.S. patents for an HIV prevention pill
For the second time this month, Gilead Sciences (GILD) has lost a bid to invalidate…
Category: Pharmalot
STAT Plus: Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence
As out-of-pocket costs rise for medicines used to treat certain neurologic disorders — such as…
STAT Plus: Pharmalittle: Need cheap insulin? Try Craigslist; Trump warned about monopolies on coronavirus treatments
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Lawmakers to Trump: Don’t give ‘monopolies’ to companies that develop coronavirus treatments with taxpayer funds
Nearly four dozen lawmakers asked the White House to ensure any treatment for the fast-moving…
How many? The coronavirus is prompting a burst of clinical trials in search of a treatment
The coronavirus sweeping across China has triggered a burst of research activity aimed at finding…
STAT Plus: Pharma execs criticize a drug maker over pricing and claim orphan drug law is being misused
Several prominent biotech and pharmaceutical executives are openly criticizing a huge price hike for a…
STAT Plus: Pharmalittle: Prices for active ingredients rise in China due to coronavirus; Grassley presses his drug pricing bill
Top of the morning, and a fine one it is. Warm and sunny skies are…
STAT Plus: Consumer groups and unions try again to block the AbbVie and Allergan merger
A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to…
STAT Plus: Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: A city in Georgia is the latest to sue Mallinckrodt over its pricey Acthar Gel medicine
The city of Marietta, Ga., has joined a growing list of unions and local governments…
STAT Plus: Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Americans with employer coverage saw growth in drug spending outpace other medical costs
Americans with private employer health insurance spent nearly 26% more on prescription drugs from 2014…
STAT Plus: As opioid crisis intensified, many family doctors found promotional pitches were very good
As the opioid crisis accelerated a decade ago, pharmaceutical sales reps emphasized the benefits of…
STAT Plus: Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management
Top of the morning to you, and a fine one, it is. Despite another round…
STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins
Amid growing rancor over the cost of insulin, two of the largest manufacturers are objecting…
STAT Plus: Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets
For years, hospitals and clinics have used an injectable medicine called dehydrated alcohol to treat…
STAT Plus: WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’
Over the past month, the World Health Organization and the Access to Medicines Foundation issued…
STAT Plus: Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy
The California Board of Pharmacy is accusing McKesson (MCK), the large pharmaceutical wholesaler, of selling…
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share…
STAT Plus: Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights
In an unusual move, the U.S. Embassy in the Netherlands is taking the Dutch government…
STAT Plus: Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Years later, raw clinical trial data tells us the extent of Avandia’s heart risks
File this under “What a difference patient-level data can make.” In 2007, controversy flared over…
STAT Plus: Gilead loses its challenge to a pair of U.S. patents over an HIV prevention pill
In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate…
STAT Plus: Pharmalittle: Trump claims on drug prices are mostly false; Merck to spin off old drugs into new company
Good morning, everyone, and welcome to the middle of the week, which arrived rather quickly,…
STAT Plus: A former Taro Pharma executive is indicted in generic price-fixing probe
A former senior executive at Taro Pharmaceuticals USA was indicted for his role in a…
STAT Plus: Pharma execs argue new Canadian regulations for setting drug prices will hurt the country
As Canada gets set to implement new regulations designed to cut prescription drug spending, the…
STAT Plus: FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake
As frustration mounts over the slower-than-expected uptake of biosimilars in the marketplace, two U.S. federal…
STAT Plus: Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT Plus: If Medicare negotiated insulin prices like the VA, it could have saved billions
As insulin becomes a poster child for the growing outcry over the cost of medicines,…
STAT Plus: Pharmalittle: FDA approves peanut allergy drug; employer coalition likes House drug pricing bill
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: PBMs favor their own pharmacies in the Florida Medicaid program
As angst rises over the prices paid for medicines, a new analysis finds some pharmacy…
STAT Plus: Pharmalittle: Trump gives states a tool to lower drug costs, with a catch; ICER updates how it assesses drugs
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT Plus: U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment
In an unexpected move, the Department of Health and Human Services will allow Novartis (NVS)…
STAT Plus: Most innovative cancer drugs take too long to reach patients in the U.K.
Despite giddy advances in treating cancer, a new analysis finds needed medicines have been reaching…
STAT Plus: Pharmalittle: Drug prices forecast to rise 3.6%; House committee considers bill to update generic labels
Rise and shine, everyone, another busy day is on the way. Our short person has…
STAT Plus: Pharmalittle: Novartis says coronavirus not disrupting supply chain, for now; FDA releases new gene therapy policies
Good morning, everyone, and welcome to the middle of the week. You made it this…
STAT Plus: The FDA wants to know how Instagram influencers sway patient views on medicines
In 2015, Kim Kardashian promoted a morning-sickness pill to her millions of followers on social…
Drug makers face more securities-fraud lawsuits, and so do cannabis companies
The number of class-action lawsuits claiming securities fraud committed by life sciences companies climbed to…
STAT Plus: Pharmalittle: Insulin dominates Democrats’ health agenda in Iowa; FDA studies Instagram influencers
Good morning, everyone. The world is watching China, the new coronavirus, and the outbreak’s spread….
.jpg)
Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market
More than four years after Martin Shkreli incensed Americans by raising the price of a…
STAT Plus: Big drug purchasers predict price hikes driven by expensive new therapies
More than two dozen big buyers of prescription medicines expect that prices will rise by…
STAT Plus: McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments
As pressure mounts on pharmaceutical wholesalers over their role in the opioid crisis, McKesson (MCK)…
STAT Plus: McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments
As pressure mounts on pharmaceutical wholesalers over their role in the opioid crisis, McKesson (MCK)…
STAT Plus: Roche is fined by Romania for thwarting competition to its cancer medicines
Following a two-year investigation, Roche (RHHBY) was fined $14 million by antitrust authorities in Romania…
STAT Plus: Pharmalittle: Coronavirus spread may hurt pharma’s supply chain; Illinois limits out-of-pocket insulin costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
‘The time to worry is now’: The coronavirus in China could threaten pharma’s ingredient sourcing
As a novel coronavirus spreads through China and rattles the rest of the world, the…